

METHODS IN MOLECULAR BIOLOGY

Series Editor

John M. Walker

School of Life and Medical Sciences

University of Hertfordshire

Hatfield, Hertfordshire, AL10 9AB, UK

For further volumes:

<http://www.springer.com/series/7651>

Drug Safety Evaluation

Methods and Protocols

Second Edition

Edited by

Jean-Charles Gautier

Preclinical Safety, Sanofi, R&D, Vitry-sur-Seine, France

 **Humana Press**

Editor

Jean-Charles Gautier
Preclinical Safety
Sanofi, R&D
Vitry-sur-Seine, France

ISSN 1064-3745 ISSN 1940-6029 (electronic)
Methods in Molecular Biology
ISBN 978-1-4939-7170-1 ISBN 978-1-4939-7172-5 (eBook)
DOI 10.1007/978-1-4939-7172-5

Library of Congress Control Number: 2017944283

© Springer Science+Business Media LLC 2017

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Printed on acid-free paper

This Humana Press imprint is published by Springer Nature
The registered company is Springer Science+Business Media LLC
The registered company address is: 233 Spring Street, New York, NY 10013, U.S.A.

Preface

Nonclinical drug safety evaluation is the assessment of the safety profile of therapeutic agents through the conduct of laboratory studies in *in vitro* systems and in animals. The main objectives of drug safety evaluation studies are to differentiate between new drug entities that are unacceptably toxic and those that are not, characterize the potential adverse effects of new drugs, determine animal dosage levels that do not cause toxicity, and estimate safe dosages to be used in clinical studies. Several types of studies are conducted in drug safety evaluation: acute to chronic general toxicity studies, reproductive toxicity studies, genotoxicity studies, carcinogenicity studies, safety pharmacology studies, and investigative toxicity studies.

The volume *Drug Safety Evaluation Methods and Protocols* was published as an earlier edition in the *Methods in Molecular Biology* series in 2011. In this second edition, some of the chapters from the previous edition have been updated to take into account the most recent advances in this field. In addition, several new chapters have been added to describe innovative tools and methods that have been developed and applied in the last 6 years to improve the safety evaluation of new drug candidates. Part I presents specific aspects related to the experimental design of toxicity studies conducted to support combination drugs in humans and pediatric indications. Part II focuses on Pathology with two chapters on detailed procedures of necropsy, tissue sampling, and processing for histopathological evaluation, and one chapter on the principles and methods of immunohistochemistry. A new chapter describes the applications of mass spectrometry imaging which are gaining more and more interest to detect and map compounds within tissue sections, thus providing useful information on drug distribution in relation to histopathological findings. Part III provides detailed protocols on Genetic Toxicology. A chapter describes the comet assay, a sensitive electrophoretic method for measuring DNA strand breaks at the level of single cells, together with the use of bacterial repair endonucleases to detect specific DNA lesions. Two new chapters describe recent advancements of the *Pig-a* mutation assay, which is anticipated to be a useful trans-species tool for evaluating the *in vivo* mutagenicity of chemicals and has been proposed as a new tool for preclinical safety assessment of regulated chemicals. Part IV provides methods on Safety Pharmacology, in which progress has been made to early evaluate the cardiotoxicity liability of new drug candidates. A new chapter describes how automatization procedures can be used to replace the resources and time-consuming manual patch-clamp approach for the hERG cardiac potassium channel. Another new chapter describes a method for measuring the contractility of induced human pluripotent stem cell derived cardiomyocytes using an impedance measurement system. Part V details methods on Investigative Toxicology aimed at better understanding mechanisms of toxicity and assessing potential translation to humans. Several chapters from the first edition have been updated on protocols and applications of nuclear magnetic resonance and mass spectrometry methods for metabolomics in several biological matrices, statistical analysis of real-time reverse transcription polymerase chain reaction (RT-PCR) which is a benchmark technology to detect and quantify mRNAs, and *in vitro* evaluation of mitochondrial respiration in cultured rat hepatocytes. A new chapter has been added on the early *in silico* evaluation of target safety, an approach which has now proven to be an invaluable resource

to support both drug discovery and development phases. Part VI is dedicated to screening assays for Developmental Toxicity. Two chapters provide detailed protocols of the Fetax assay and the Zebrafish model. Part VII encompasses methods to identify and characterize novel translational safety biomarkers to better monitor potential toxicity of drug candidates in both preclinical and clinical studies. One chapter provides protocols on the absolute quantification of protein safety biomarkers by mass spectrometry. Given that there is a growing interest to explore microRNAs as potential novel safety biomarkers in biofluids, several new chapters have been included to describe how next-generation sequencing, quantitative RT-PCR, and in situ hybridization technologies can be applied to investigate microRNAs for this purpose. A new chapter has also been added on the isolation and characterization of urine exosomes, which can potentially be used to detect nephrotoxicity.

I would like to thank all the contributing authors for providing state-of-the-art procedures, detailed protocols, and tips and tricks to avoid pitfalls. I am grateful to the series editor, John Walker, for inviting me to edit this second edition of the volume. The result is a compendium of analytical technologies, including some review chapters, with a focus on clarity and applicability in real life laboratory practice. The intended audience mainly consists of pharmaceutical scientists, toxicologists, biochemists, and molecular biologists, and anyone else with a specific interest for a method used in drug safety evaluation that could be used in other disciplines.

Vitry-sur-Seine, France

Jean-Charles Gautier

Contents

<i>Preface</i>	<i>v</i>
<i>Contributors</i>	<i>ix</i>
PART I GENERAL TOXICOLOGY	
1 Nonclinical Development of Combination Drugs	3
<i>Alberto Lodola</i>	
2 Juvenile Nonclinical Safety Studies in Support of Pediatric Drug Development	25
<i>Paul C. Barrow and Georg Schmitt</i>	
PART II PATHOLOGY	
3 Procedures of Necropsy and Tissue Sampling	71
<i>Laurence Fiette, Mohamed Slaoui, and Anne-Laure Bauchet</i>	
4 Tissue Sampling and Processing for Histopathology Evaluation	101
<i>Mohamed Slaoui, Anne-Laure Bauchet, and Laurence Fiette</i>	
5 Principles and Methods of Immunohistochemistry	115
<i>José A. Ramos-Vara</i>	
6 Applications of Mass Spectrometry Imaging for Safety Evaluation	129
<i>David Bonnel and Jonathan Stauber</i>	
PART III GENETIC TOXICOLOGY	
7 In Vivo Rat T-Lymphocyte <i>Pig-a</i> Assay: Detection and Expansion of Cells Deficient in the GPI-Anchored CD48 Surface Marker for Analysis of Mutation in the Endogenous <i>Pig-a</i> Gene	143
<i>Vasily N. Dobrovolsky, Javier Revollo, Dayton M. Petibone, and Robert H. Heflich</i>	
8 Detection of In Vivo Mutation in the <i>Pig-a</i> Gene of Mouse Bone Marrow Erythroids	161
<i>Takafumi Kimoto and Daishiro Miura</i>	
9 The Use of Bacterial Repair Endonucleases in the Comet Assay	173
<i>Andrew R. Collins</i>	
PART IV SAFETY PHARMACOLOGY	
10 Automated Patch-Clamp Methods for the hERG Cardiac Potassium Channel	187
<i>Sylvie Houtmann, Brigitte Schombert, Camille Sanson, Michel Partiseti, and G. Andrees Bohme</i>	
11 Impedance Measurement in Induced Pluripotent Stem Cell-Derived Cardiomyocytes	201
<i>Emma-Jane Poulton</i>	

PART V INVESTIGATIVE TOXICOLOGY

- 12 Target Safety Assessment: Strategies and Resources 213
Richard J. Brennan
- 13 NMR and MS Methods for Metabolomics. 229
Alexander Amberg, Björn Riefke, Götz Schlotterbeck, Alfred Ross, Hans Senn, Frank Dieterle, and Matthias Keck
- 14 Protocols and Applications of Cellular Metabolomics in Safety Studies Using Precision-Cut Tissue Slices and Carbon 13 NMR 259
Gabriel Baverel, Maha El Hage, and Guy Martin
- 15 Statistical Analysis of Quantitative RT-PCR Results 281
Richard Khan-Malek and Ying Wang
- 16 Evaluation of Mitochondrial Respiration in Cultured Rat Hepatocytes 297
Jean-Pierre Marchandean and Gilles Labbe

PART VI SCREENING ASSAYS FOR DEVELOPMENTAL TOXICITY

- 17 FETAX Assay for Evaluation of Developmental Toxicity 311
Isabelle Mouche, Laure Malésic, and Olivier Gillardeaux
- 18 Evaluation of Embryotoxicity Using the Zebrafish Model 325
Lisa Truong and Robert L. Tanguay

PART VII SAFETY BIOMARKERS

- 19 Absolute Quantification of Toxicological Biomarkers via Mass Spectrometry. 337
Thomas Y. K. Lau, Ben C. Collins, Peter Stone, Ning Tang, William M. Gallagher, and Stephen R. Pennington
- 20 Next-Generation Sequencing to Investigate Urinary microRNAs from *Macaca fascicularis* (Cynomolgus Monkey) 349
Yaligara Veeranagouda, Jean-François Léonard, Jean-Charles Gautier, and Eric Boitier
- 21 Quantitative RT-PCR for MicroRNAs in Biofluids 379
Michael Thorsen, Thorarinn Blondal, and Peter Mouritzen
- 22 Chromogenic In Situ Hybridization Methods for microRNA Biomarker Monitoring of Drug Safety and Efficacy 399
Barbara R. Gould, Tina Damgaard, and Boye Schnack Nielsen
- 23 Urine Exosome Isolation and Characterization 413
Jonathan M. Street, Erik H. Koritzinsky, Deonna M. Glispie, and Peter S.T. Yuen
- Index*. 425

Contributors

- ALEXANDER AMBERG • *Preclinical Safety, Sanofi R&D, Hattersheim, Germany*
- PAUL C. BARROW • *Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland*
- ANNE-LAURE BAUCHET • *Translational Medicine and Early Development, Biomarkers and Clinical Bioanalyses, Sanofi R&D, Vitry-sur-Seine, France*
- GABRIEL BAVEREL • *Metabolys Inc., Lyon, France*
- THORARINN BLONDAL • *Exiqon A/S, Vedbæk, Denmark*
- G. ANDREES BOHME • *Integrated Drug Discovery, Sanofi R&D, Vitry-sur-Seine, France*
- ERIC BOITIER • *Translational Medicine and Early Development, Biomarkers and Clinical Bioanalyses—Genomics, Sanofi R&D, Vitry-sur-Seine, France*
- DAVID BONNEL • *ImaBiotech, Parc Eurasanté, Loos, France*
- RICHARD J. BRENNAN • *Sanofi, Waltham, MA, USA*
- BEN C. COLLINS • *Institute of Molecular Systems Biology, ETH Zürich, Switzerland*
- ANDREW R. COLLINS • *Department of Nutrition, University of Oslo, Oslo, Norway*
- TINA DAMGAARD • *Exiqon A/S, Vedbæk, Denmark*
- FRANK DIETERLE • *New Products and Medical, Near Patient Testing, Novartis, Basel, Switzerland*
- VASILY N. DOBROVOLSKY • *Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR, USA*
- LAURENCE FIETTE • *IMMR, Paris, France*
- WILLIAM M. GALLAGHER • *School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland*
- JEAN-CHARLES GAUTIER • *Preclinical Safety, Sanofi, R&D, Vitry-sur-Seine, France*
- OLIVIER GILLARDEAUX • *Paris, France*
- DEONNA M. GLISPIE • *Renal Diagnostics and Therapeutics Unit, NIDDK, National Institutes of Health, Bethesda, MD, USA*
- BARBARA R. GOULD • *Exiqon Inc., Woburn, MA, USA*
- MAHA EL HAGE • *Metabolys Inc., Lyon, France*
- ROBERT H. HEFLICH • *Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR, USA*
- SYLVIE HOUTMANN • *Integrated Drug Discovery, Sanofi R&D, Vitry-sur-Seine, France*
- MATTHIAS KECK • *Analytical Development 1, Bayer Pharma AG, Wuppertal 42096, Germany*
- RICHARD KHAN-MALEK • *Biostatistics and Programming, Sanofi US, Inc., Bridgewater, NJ, USA*
- TAKAFUMI KIMOTO • *Toxicology Research Department, Teijin Institute for Bio-medical Research, Teijin Pharma Limited, Hino, Tokyo, Japan*

- ERIK H. KORITZINSKY • *Renal Diagnostics and Therapeutics Unit, NIDDK, National Institutes of Health, Bethesda, MD, USA*
- GILLES LABBE • *Investigative Toxicology, Preclinical Safety, Sanofi R&D, Vitry-sur-Seine, France*
- THOMAS Y.K. LAU • *Pfizer Inc., Andover, MA, USA*
- JEAN-FRANÇOIS LÉONARD • *Translational Medicine and Early Development, Biomarkers and Clinical Bioanalyses—Genomics, Sanofi R&D, Vitry-sur-Seine, France*
- ALBERTO LODOLA • *ToxAdvantage, Noizay, France*
- LAURE MALÉSIC • *Paris, France*
- JEAN-PIERRE MARCHANDEAU • *Investigative Toxicology, Preclinical Safety, Sanofi R&D, Vitry-sur-Seine, France*
- GUY MARTIN • *Metabolys Inc., Lyon, France*
- DAISHIRO MIURA • *Toxicology Research Department, Teijin Institute for Bio-medical Research, Teijin Pharma Limited, Hino, Tokyo, Japan*
- ISABELLE MOUCHE • *GenEvolutioN, Rosny-sur-Seine, France*
- PETER MOURITZEN • *Exiqon A/S, Vedbæk, Denmark*
- BOYE SCHNACK NIELSEN • *Bioneer A/S, Hørsholm, Denmark*
- MICHEL PARTISETI • *Integrated Drug Discovery, Sanofi R&D, Vitry-sur-Seine, France*
- STEPHEN R. PENNINGTON • *UCD School of Medicine and Medical Science, UCD Conway Institute, Dublin, Ireland*
- DAYTON M. PETIBONE • *Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR, USA*
- EMMA-JANE POULTON • *Preclinical Safety, Sanofi, Framingham, MA, USA*
- JOSÉ A. RAMOS-VARA • *Department of Comparative Pathobiology, Purdue University, West Lafayette, IN, USA*
- JAVIER REVOLLO • *Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR, USA*
- BJÖRN RIEFKE • *Investigational Toxicology, Metabolic Profiling and Clinical Pathology, Bayer Pharma AG, Berlin, Germany*
- ALFRED ROSS • *Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland*
- CAMILLE SANSON • *Integrated Drug Discovery, Sanofi R&D, Vitry-sur-Seine, France*
- GÖTZ SCHLOTTERBECK • *School of Life Sciences, Institute for Chemistry and Bioanalytics, University of Applied Sciences, Northwestern Switzerland, Muttenz, Switzerland*
- GEORG SCHMITT • *Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland*
- BRIGITTE SCHOMBERT • *Integrated Drug Discovery, Sanofi R&D, Vitry-sur-Seine, France*
- HANS SENN • *Heythrop College UCL, Kensington Square, London, UK*
- MOHAMED SLAOUİ • *Preclinical Safety, Sanofi R&D, Vitry-sur-Seine, France*
- JONATHAN STAUBER • *ImaBiotech, Parc Eurasanté, Loos, France*
- PETER STONE • *Agilent Technologies, Santa Clara, CA, USA*
- JONATHAN M. STREET • *Renal Diagnostics and Therapeutics Unit, NIDDK, National Institutes of Health, Bethesda, MD, USA*

NING TANG • *Agilent Technologies, Santa Clara, CA, USA*

ROBERT L. TANGUAY • *Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, USA; Sinnhuber Aquatic Research Laboratory, Oregon State University, Corvallis, OR, USA*

MICHAEL THORSEN • *Exiqon A/S, Vedbæk, Denmark*

LISA TRUONG • *Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, USA; Sinnhuber Aquatic Research Laboratory, Oregon State University, Corvallis, OR, USA*

YALIGARA VEERANAGOUDA • *Molecular Biology & Genomics, Translational Science, Sanofi R&D, Chilly-Mazarin, France*

YING WANG • *Translational Medicine and Early Development, Sanofi US, Inc., Bridgewater, NJ, USA*

PETER S.T. YUEN • *Renal Diagnostics and Therapeutics Unit, NIDDK, National Institutes of Health, Bethesda, MD, USA*